Jeong Min Yu, MD, MS, and other medical officers from the U.S. Food and Drug Administration discussed approvals including a Janus kinase and tyrosine kinase 2 inhibitor for dermatomyositis and an interleukin-23 antagonist for psoriatic arthritis, both for the treatment of adults.
Stephanie Faubion, MD, MBA, and Karen Costenbader, MD, MPH, reviewed new evidence about the value of hormone therapy for patients with autoimmune disease in menopause and post menopause.
Laura Passalent, BSc, PT, MHS, and other experienced clinicians will explain how such collaboration can streamline access to care, open up provider schedules, and give people living with rheumatic disease more control over their lives.
Michael Weintraub, MD, and Veena K. Ranganath, MD, MS, RhMSUS, will discuss the evolving landscape of glucagon-like peptide-1 receptor agonists and current evidence for the use of this kind of incretin therapy in rheumatologic diseases.
In two lectures across two days, Varitka Kesarwani, MBBS, will review the mechanisms of immunology to help attendees build a mental framework they can leverage in the clinic.
ABSTRACT: Hilbert Nguyen, PT, DPT
Experts will provide an overview of the immunobiology of cellular therapies for rheumatic diseases, examine which diseases might be most responsive to these therapies, share results from recent clinical trials, and debate the correct pace for the widespread use of cellular therapy in rheumatology.
ABSTRACT: Ann-Christin Pecher, MD